Published Guidance, NICE advice and quality standards

Showing 26 to 34 of 34

Sort by

Published guidance, NICE advice and quality standards
Title	Reference number	Published	Last updated
Denosumab for preventing skeletal-related events in multiple myeloma (terminated appraisal)	TA549	5 December 2018	5 December 2018
Bortezomib for treating multiple myeloma after second or subsequent relapse (terminated appraisal)	TA453	5 July 2017	5 July 2017
Daratumumab with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal)	TA454	5 July 2017	5 July 2017
Elotuzumab for previously treated multiple myeloma (terminated appraisal)	TA434	22 March 2017	22 March 2017
Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomib	TA427	11 January 2017	11 January 2017
Panobinostat for treating multiple myeloma after at least 2 previous treatments	TA380	27 January 2016	27 January 2016
Bortezomib for induction therapy in multiple myeloma before high-dose chemotherapy and autologous stem cell transplantation	TA311	23 April 2014	23 April 2014
Bortezomib and thalidomide for the first‑line treatment of multiple myeloma	TA228	27 July 2011	27 July 2011
Bortezomib monotherapy for relapsed multiple myeloma	TA129	23 October 2007	23 October 2007